Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20758808 | 0.95 | GRM4 (1.00) | GRM4 | |
| SCHEMBL20758884 | 0.88 | GRM4 (1.00) | GRM4 | |
| SCHEMBL20758705 | 0.88 | GRM4 (1.00) | GRM4 | |
| SCHEMBL20759068 | 0.87 | GRM4 (1.00) | GRM4 | |
| SCHEMBL20741058 | 0.85 | GRM4 (0.73) | GRM4 | |
| SCHEMBL20758711 | 0.84 | GRM4 (1.00) | GRM4 | |
| SCHEMBL20758880 | 0.84 | GRM4 (1.00) | GRM4 | |
| SCHEMBL20758890 | 0.84 | GRM4 (1.00) | GRM4 | |
| SCHEMBL20758882 | 0.82 | GRM4 (1.00) | GRM4 | |
| SCHEMBL22035117 | 0.81 | GRM4 (1.00) | GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070897-A1 | INDAZOLE COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | UNIV VANDERBILT (US) | 2026-03-12 | — | — | US | disclosed |
| US-12291521-B2 | Indazole compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2025-05-06 | — | — | US | disclosed |
| US-11427573-B2 | Indazole compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2022-08-30 | — | — | US | disclosed |
| US-20220259190-A1 | INDAZOLE COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY | 2022-08-18 | — | — | US | disclosed |
| US-20200291019-A1 | INDAZOLE COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY | 2020-09-17 | — | — | US | disclosed |
| US-20200291019-A1 | INDAZOLE COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY | 2020-09-17 | — | — | US | disclosed |
| EP-3668865-A1 | INDAZOLE COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | Vanderbilt University (US) | 2020-06-24 | — | — | EP | disclosed |
| CN-111225913-A | Indazole compounds as allosteric enhancers of MGLUR4, compositions, and methods of treating neurological dysfunction | 范德比尔特大学 | 2020-06-02 | — | — | CN | disclosed |
| WO-2019036534-A1 | INDAZOLE COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY (US) | 2019-02-21 | — | — | WO | disclosed |
| US-20190055225-A1 | INDAZOLE COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY | 2019-02-21 | — | — | US | disclosed |
| US-20190055225-A1 | INDAZOLE COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY | 2019-02-21 | — | — | US | disclosed |
| WO-2019036534-A1 | INDAZOLE COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY (US) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070897-A1 | INDAZOLE COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | GRM1, GRM2, GRM3 | GRM4 5/4885 |
| US-20220259190-A1 | INDAZOLE COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | GRIK4, GRM4, GRIK3 | GRM4 2/4885 |
| US-20200291019-A1 | INDAZOLE COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | GRIK4, GRM4, GRIK3 | GRM4 2/4885 |
| US-20190055225-A1 | INDAZOLE COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | GRIK4, GRM4, GRIK3 | GRM4 2/4885 |
| US-12291521-B2 | Indazole compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | GRIK4, GRM4, GRIK3 | GRM4 2/4885 |
| US-11427573-B2 | Indazole compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | GRIK4, GRM4, GRIK3 | GRM4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.